Guide

Stimulants by Telehealth to a Patient You've Never Seen In Person

Summary

A psychiatric mental health nurse practitioner can prescribe a stimulant by telehealth to a patient never seen in person, through December 31, 2026, because DEA's temporary rule at 21 CFR 1307.41 suspends the Ryan Haight in-person evaluation requirement for Schedule II through V. Four conditions ride on every prescription, including registration authority for that class of controlled substance and consistency with the Schedule II rules on refills and multiple prescriptions. The authorization expires at the end of that day unless DEA extends or replaces it.

By Gale Editorial · Updated 2026-09-01. Every figure cited to a dated source. How we write.

Can a PMHNP prescribe a stimulant to a patient never seen in person?

Yes, through the end of the day on December 31, 2026. The codified flexibility at 21 CFR 1307.41(b) authorizes a DEA-registered practitioner to prescribe schedule II through V controlled substances via telemedicine to a patient without having conducted an in-person medical evaluation, provided every condition in paragraph (c) is met 1. Schedule II sits inside that range, so for a patient the prescriber has never met, prescribing without an in-person exam is exactly what the section permits.

That permission carries its own end date. It is in effect until the end of the day December 31, 2026, and the authorization granted in paragraph (b) expires at the end of that day 1. The window exists because DEA and SAMHSA issued a fourth extension of the telemedicine flexibilities, effective January 1, 2026 through December 31, 2026 2.

Underneath it is the Ryan Haight baseline. 21 U.S.C. 829(e) defines a valid prescription issued by means of the Internet as one written by a practitioner who has conducted at least one in-person medical evaluation of the patient, or by a covering practitioner 3. That statute is what the temporary rule suspends.

The four conditions that ride on every prescription

Paragraph (c) of 21 CFR 1307.41 attaches four conditions, and paragraph (b) authorizes the prescription only if every one of them is met 1. Two of them are cross-references, which is the part that catches people. The prescription must be issued pursuant to a communication between practitioner and patient using an interactive telecommunications system referred to in 42 CFR 410.78(a)(3), and it must be consistent with all other requirements of 21 CFR part 1306 1.

The other two are the familiar ones. The prescription has to be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice, and the practitioner has to be authorized under their registration to prescribe that basic class of controlled substance, or exempt from obtaining a registration 1. Paragraph (c) never names your state's controlled-substance statute. State law reaches the prescription through the Part 1306 cross-reference and through the license the registration rests on, which is why the state question is not optional even though the section is silent on it.

But the condition is written about the system the communication used, so it is a condition about what happened in the visit itself. The dropped call is where that bites: a session that starts on video and finishes on the phone changes the answer to the question the regulation asks. Read the telehealth-prescribing conditions as a per-prescription test, read 42 CFR 410.78(a)(3) itself before relying on audio-only, and record which system carried each encounter.

What the flexibility does not change about Schedule II

The flexibility does not touch Part 1306, and Part 1306 is where the stimulant-specific work sits. Refilling a prescription for a controlled substance listed in Schedule II is prohibited 4. The statute says the same thing at 21 U.S.C. 829(a) 3. Telehealth changes none of that, so a patient you have never met still needs a separate prescription for each fill.

What the regulation allows instead is a sequence. A practitioner may issue multiple prescriptions authorizing a patient to receive a total of up to a 90-day supply, but only where every one of the five conditions in 21 CFR 1306.12(b)(1) is satisfied, and one of those conditions is that issuing them be permissible under applicable state laws 4.

The federal text sets a ceiling. Your own state's controlled-substance statute decides whether you can reach it, and the condition itself points you there.

Audio-only, and why the buprenorphine guidance does not transfer

Treat audio-only as unsettled for a Schedule II stimulant. The fourth temporary rule describes the flexibilities as having authorized practitioners to prescribe Schedule II through V controlled medications via audio-video telemedicine encounters, and describes audio-only encounters in connection with Schedule III through V narcotic medications approved for maintenance and withdrawal management treatment of opioid use disorder 2. That is preamble description, the closest anchor the federal text offers.

As of September 1, 2026, SAMHSA's buprenorphine questions and answers set out a separate pathway with its own shape: initiation by audio-only or audio-visual telemedicine for a patient never examined in person, a prescription drug monitoring program check that is documented, and a six-month total supply ceiling under that pathway 5. It is a rule about one medication for one condition.

Reading that pathway as permission to start a stimulant over the phone is the common mistake, and an easy one, because the two pathways are written in the same vocabulary. Nothing in the operative federal text says an audio-only encounter satisfies the interactive-telecommunications condition for a Schedule II prescription.

Where you are registered, and where the patient is

A DEA registration rests on a state license. DEA's own Practitioner's Manual states that state authority confers rights and privileges only within the issuing state, so a registration based on one state's license cannot authorize controlled-substance dispensing outside that state 6. The telemedicine flexibility says nothing about how many registrations a practitioner holds. It suspends an in-person requirement and leaves the geography of your license where it was.

The rule under everything is where the patient sits at the time of the visit. Prescribing after a video-only intake to a patient in a state where you hold neither a license nor a registration puts you outside the authority the flexibility assumes.

Registration is also tied to a location. Section 1301.12(a) requires a separate registration for each principal place of business or professional practice at one general physical location where controlled substances are dispensed 7. The exemption that matters to a telehealth-only practice sits in the same section: an office in the same state where the practitioner only prescribes, keeps no supply, and does not administer or dispense does not require its own registration 7. Read that threshold literally, because keeping any supply at a second site moves a practice across it.

A PMHNP is what DEA calls a mid-level practitioner, a category defined by the authority of the jurisdiction in which the practitioner practices 6. Prescriptive authority, any collaboration requirement, and any state-level telehealth registrations are settled by your board before the federal question arises. The telehealth prescribing state rules that bind you are your board's, and they can be narrower than the federal ceiling.

Being allowed to prescribe and being paid for the visit

Being allowed to prescribe and being paid for the visit are two rule sets on two clocks, and clearing one does not clear the other. DEA decides whether the prescription is lawful. Medicare decides whether the telehealth visit that produced it is payable, under its own behavioral-health telehealth provisions, including the conditions on the home as an originating site, the conditions on audio-only encounters, and the in-person visit requirements as amended 8.

A prescription can be lawful under 21 CFR 1307.41 and the visit behind it still not billable. Check the CMS telehealth booklet for the eligibility conditions and the billing specifics before the first telehealth follow-up rather than after the claim 8, and read your commercial contracts separately.

What to do before December 31, 2026

Calendar the date, then decide which of two paths each patient is on. Every rule for prescribing controlled substances by telehealth to a patient never examined in person sits in one temporary section, and it expires at the end of the day December 31, 2026 1. DEA has published no permanent replacement, and the framework it proposed in January 2025 remains a proposal as of September 1, 2026 9.

One in-person medical evaluation, whenever it happens, ends the Ryan Haight remote-prescribing restriction for that practitioner and that patient. DEA states that once a practitioner has conducted at least one in-person medical evaluation, the remote-prescribing requirements no longer apply to that practitioner-patient relationship, permitting remote prescribing indefinitely regardless of how much time has passed, so long as the prescriptions are for a legitimate medical purpose in the usual course of practice and comply with other federal and state law 2. For a panel that will still be on a stimulant in 2027, that is the one durable answer available now.

The proposal is worth reading, in the conditional. It would establish a special registration framework authorizing three types of special registration, with heightened prescription, recordkeeping and reporting requirements 9. As proposed, a multi-state prescriber would hold one on top of a conventional registration, plus a state telemedicine registration for each state where a telemedicine patient is located. The proposed fee is $888, with a discounted $50 per state on a three-year cycle 9. None of that is in force, and a final rule in another form would change the numbers with it.

Four things to hold, on paper, before the window closes:

  • Watch 21 CFR 1307.41 and Federal Register docket DEA-407, where the fourth extension was published, rather than a summary page that lags it.
  • Record, for every patient started under the flexibility, whether an in-person evaluation has ever occurred and with which practitioner.
  • Confirm the state rule for each patient's location before the first fill, since the federal condition defers to it either way.
  • Keep the telehealth registrations and licenses that carry your prescriptive authority on their own renewal calendar, separate from the DEA one.

As of September 1, 2026 the fourth extension is still the newest document in DEA docket DEA-407 2, and DEA's own telemedicine page still states it is drafting updated regulations 10. Re-check the section itself before you rely on it.

Common questions

Through December 31, 2026, yes, if every condition in 21 CFR 1307.41(c) is met. Those four are a legitimate medical purpose in the usual course of professional practice, an interactive telecommunications system, registration authority to prescribe that basic class of controlled substance or an exemption from registration, and consistency with all other Part 1306 requirements. State law can be narrower and controls where it is.

No. Refilling a Schedule II prescription is prohibited, and the telemedicine flexibility does not touch that rule. What the regulation permits instead is multiple prescriptions issued at once, together authorizing up to a 90-day total supply, and only where all five conditions in 21 CFR 1306.12(b)(1) are satisfied, one of which is that the practice be permissible under applicable state laws.

Treat it as unsettled. The temporary rule describes the flexibility in terms of audio-video encounters for Schedule II through V, and describes audio-only encounters in connection with Schedule III through V narcotic medications for opioid use disorder treatment. The operative condition points to the interactive telecommunications system definition at 42 CFR 410.78(a)(3), which is the text to read before relying on audio-only.

A DEA registration rests on a state license, and DEA states that state authority confers rights only within the issuing state, so one state's registration cannot authorize controlled-substance activity in another. Registration is also tied to a physical location, with an exemption for an office in the same state where the practitioner only prescribes, keeps no supply, and does not administer or dispense.

The Ryan Haight baseline governs again. A prescription issued by means of the Internet is valid only if written by a practitioner who has conducted at least one in-person medical evaluation of the patient, or by a covering practitioner. Patients who have had one in-person evaluation with you are unaffected by the lapse. DEA's proposed special registration framework was still a proposal as of September 1, 2026.

Run your practice on Gale

The software is free. Gale earns one flat 3.5% all-in per paid transaction — only on transactions that actually pay. No subscription, no setup fee, no network cut.

Start or manage a practice →

References

  1. 1.Drug Enforcement Administration, Department of Justice (2026). 21 CFR 1307.41 — Temporary extension of certain COVID-19 telemedicine flexibilities for prescription of controlled medications.. Electronic Code of Federal Regulations (eCFR), Title 21. link ✓The operative authorization to prescribe schedule II-V controlled substances via telemedicine without a prior in-person medical evaluation, the requirement that every condition in paragraph (c) be met, the interactive telecommunications system cross-reference to 42 CFR 410.78(a)(3), the registration-authority condition in paragraph (c)(3), the consistency-with-part-1306 condition, and the December 31, 2026 expiration stated in paragraph (a).
  2. 2.Drug Enforcement Administration, U.S. Department of Justice; Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services (2025). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, Vol. 90, No. 247, pp. 61301–61306 (90 FR 61301), Docket No. DEA-407, temporary rule, December 31, 2025. link ✓The effective window of the fourth extension (January 1, 2026 through December 31, 2026), the audio-video description of the flexibilities for Schedule II-V with audio-only described for Schedule III-V narcotic medications for opioid use disorder, DEA's statement that one in-person medical evaluation ends the remote-prescribing restriction for that practitioner-patient relationship, and that it remains the newest document in DEA docket DEA-407 as of 2026-09-01.
  3. 3.Office of the Law Revision Counsel, U.S. House of Representatives (2026). 21 U.S.C. 829 — Prescriptions. United States Code (prelim), Title 21, Chapter 13, Subchapter I. link ✓The statutory baseline the temporary rule suspends: 829(e)'s definition of a valid prescription issued by means of the Internet, requiring at least one in-person medical evaluation or a covering practitioner, and 829(a)'s prohibition on refilling a Schedule II prescription.
  4. 4.Drug Enforcement Administration, Department of Justice (2026). 21 CFR 1306.12 — Refilling prescriptions; issuance of multiple prescriptions.. Electronic Code of Federal Regulations (eCFR), Title 21. link ✓The Schedule II rules the flexibility leaves untouched: the prohibition on refilling a Schedule II prescription, and the five conditions in 1306.12(b)(1) governing multiple prescriptions authorizing up to a 90-day total supply, including that the practice be permissible under applicable state laws.
  5. 5.Substance Abuse and Mental Health Services Administration (SAMHSA) (2025). Buprenorphine Telemedicine Prescribing: Questions and Answers. SAMHSA.gov. link ✓The separate federal buprenorphine telemedicine pathway used here only as a contrast: initiation by audio-only or audio-visual telemedicine for a patient never examined in person, the documented prescription drug monitoring program check, and the six-month total supply ceiling under that pathway. As of 2026-09-01.
  6. 6.U.S. Department of Justice, Drug Enforcement Administration, Diversion Control Division (2023). Practitioner's Manual: An Informational Outline of the Controlled Substances Act. Drug Enforcement Administration, Diversion Control Division (deadiversion.usdoj.gov). link ✓DEA's plain-language statements that a DEA individual registration rests on a state license and that state authority confers rights only within the issuing state, and that a mid-level practitioner is a category defined by the authority of the jurisdiction in which the practitioner practices.
  7. 7.Drug Enforcement Administration (Code of Federal Regulations, Title 21, Part 1301) (2024). § 1301.12 Separate registrations for separate locations. Code of Federal Regulations, Title 21 — govinfo.gov (U.S. Government Publishing Office), 2024 annual edition. link ✓The rule in 1301.12(a) requiring a separate registration for each principal place of business or professional practice at one general physical location where controlled substances are dispensed, and the exemption for an office in the same state where the practitioner only prescribes, keeps no supply, and does not administer or dispense.
  8. 8.Centers for Medicare & Medicaid Services (2025). Telehealth Services. CMS Medicare Learning Network (MLN901705). link ✓That Medicare telehealth payment runs on its own rule set, including the permanent behavioral-health provisions on the home as an originating site, the audio-only conditions, and the in-person visit requirements as amended, and that the booklet is where the eligibility and billing specifics are stated.
  9. 9.Drug Enforcement Administration, U.S. Department of Justice (2025). Special Registrations for Telemedicine and Limited State Telemedicine Registrations. Federal Register, Vol. 90, No. 11, pp. 6541–6598 (90 FR 6541), Docket No. DEA-407, RIN 1117-AB40, notice of proposed rulemaking, January 17, 2025. link ✓What DEA has PROPOSED and not finalized as of 2026-09-01: three types of Special Registration with heightened prescription, recordkeeping and reporting requirements, an ancillary State Telemedicine Registration for each state where a telemedicine patient is located, a conventional registration still required underneath, and the proposed $888 Special Registration fee with the discounted $50-per-state clinician registration on a three-year cycle.
  10. 10.Drug Enforcement Administration, Diversion Control Division (2023). Telemedicine. DEA Diversion Control Division. link ✓DEA's own statement on its telemedicine page that it is still drafting updated telemedicine regulations, used only as evidence that no permanent rule has been posted there.

https://www.gale.care/for-providers/pq-pmhnp-stimulants-telehealth-never-seen-in-person · 10 sources. Competitor details are cited to dated public sources and maintained as they change; figures are estimates, not commitments. Synthetic demonstration.

← Back to for providers

Findability, by specialty

How practices like yours get found in local search and AI answers — the honest playbook, per specialty.

SEO for private practices · SEO for AI search / answer engines (all verticals)